Publications by authors named "Cloris Xue"

Claim this Profile
B
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Yun Fan, Alexander Drilon, Chao-Hua Chiu, Herbert H F Loong, Salvatore Siena, Cloris Xue

Clin Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Sara A Hurvitz, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, Isabel Blancas, Cloris Xue

Lancet Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF wild-type melanoma progressing on prior anti-programmed death-1 therapy.
Shahneen Sandhu, Victoria Atkinson, Maria González Cao, Theresa Medina, Ainara Soria Rivas, Cloris Xue

Eur J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Paolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Cloris Xue

Lancet Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.
Giulio Barteselli, Grant R Goodman, Yogesh Patel, Ivor Caro, Cloris Xue

Drug Saf· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line atezolizumab monotherapy in patients with advanced BRAF wild-type melanoma.
Sergio Jobim de Azevedo, Andreia Cristina de Melo, Louise Roberts, Ivor Caro, Cloris Xue

Pigment Cell Melanoma Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
Christine Brezden-Masley, Kelly E Fathers, Megan E Coombes, Behin Pourmirza, Cloris Xue

Breast Cancer Res Treat· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Christine Brezden-Masley, Kelly E Fathers, Megan E Coombes, Behin Pourmirza, Cloris Xue

Breast Cancer Res Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Christine Brezden-Masley, Kelly E Fathers, Megan E Coombes, Behin Pourmirza, Cloris Xue

Cancer Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis